/
Our Company On August 15, 2025, ReShape Lifesciences Inc. (now known as Vyome Holdings, Inc.) (the Company ) completed the merger pursuant to the Agreement and Plan of Merger, dated as of July 8, 2024, as amended (the Merger Agreement ), by and among the Company, Raider Lifesciences Inc., a wholly owned subsidiary of the Company ( Merger Sub ), and Vyome Therapeutics, Inc. ( Vyome ). Pursuant t…
The business is unprofitable at the operating level (-3269.35% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue grew 24.4%, still solid. Margins contracted 2877.7pp, which offsets some of the top-line progress.
ROIC dropped from -20.15% to -346.94%, capital efficiency is deteriorating. Negative free cash flow of -$4M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (TTM)
$153K
▲ +24.4% YoY
Net Income (TTM)
-$11M
▼ -609.0% YoY
Op. Margin
-7453.65%
▼ -2877.7pp YoY
ROIC
-176.69%
▼ -326.8pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$5M
▼ -510.4% YoY
Op. Cash Flow (TTM)
-$5M
▼ -510.4% YoY
Net Debt
-$9M
Net Cash Position
Cash & Equiv.
$9M
3Y CAGR: -69.5%
Continue Research